Evaluation of ceftaroline alone and in combination against biofilm-producing methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin and vancomycin in an in vitro pharmacokinetic/pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4497-4503

  Barber, Katie E ^a   Smith, Jordan R ^a   Ireland, Cortney E ^a   Boles, Blaise R ^b   Rose, Warren E ^c   Rybaka, Michael J ^a,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; DAPTOMYCIN; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; METICILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BIOFILM; COLONY FORMING UNIT; CONTROLLED STUDY; ELIMINATION HALF-LIFE; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; HALF LIFE TIME; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTI-BACTERIAL AGENTS; BIOFILMS; CEPHALOSPORINS; DAPTOMYCIN; DRUG THERAPY, COMBINATION; HALF-LIFE; METHICILLIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; VANCOMYCIN;

EID: 84939784622     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00386-15     Document Type: Article

References (32)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
2. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1-14. http://dx.doi.org/10.1086/668770.
3. Dhand A, Sakoulas G. 2012. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy. F1000 Med Rep 4:4. http://dx.doi.org/10.3410/M4-4.
4. van Hal SJ, Barbagiannakos T, Jones M, Wehrhahn MC, Mercer J, Chen D, Paterson DL, Gosbell IB. 2011. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother 66:2284-2287. http://dx.doi.org/10.1093/jac/dkr280.
5. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23:99-139. http://dx.doi.org/10.1128/CMR.00042-09.
6. Römling U, Balsalobre C. 2012. Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med 272:541-561. http://dx.doi.org/10.1111/joim.12004.
7. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167-193. http://dx.doi.org/10.1128/CMR.15.2.167-193.2002.
8. Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2:95-108. http://dx.doi.org/10.1038/nrmicro821.
9. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR, Infectious Diseases Society of America. 2013. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 56:e1-e25. http://dx.doi.org/10.1093/cid/cis803.
10. Barber KE, Werth BJ, Rybak MJ. 2015. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. J Antimicrob Chemother 70:505-509. http://dx.doi.org/10.1093/jac/dku378.
11. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. 2013. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 57:66-73. http://dx.doi.org/10.1128/AAC.01586-12.
12. Barber KE, Werth BJ, McRoberts JP, Rybak MJ. 2014. A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 58:2989-2992. http://dx.doi.org/10.1128/AAC.02764-13.
13. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. 2010. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 54:4329-4334. http://dx.doi.org/10.1128/AAC.00455-10.
14. nd informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA. http://antimicrobianos.com.ar/ATB/wp-content/uploads/2012/11/M100S22E.pdf.
15. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771-1776.
16. Saravolatz LD, Stein GE, Johnson LB. 2011. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 52:1156-1163. http://dx.doi.org/10.1093/cid/cir147.
17. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50:3245-3249. http://dx.doi.org/10.1128/AAC.00247-06.
18. Merrell Dow Pharmaceuticals, Inc. 2000. Rifadin(R), rifampin capsules and injection package insert. Merrell Dow Pharmaceuticals, Inc., Kansas City, MO.
19. Bennett WM, Aronoff GR, Morrison G, Golper TA, Pulliam J, Wolfson M, Singer I. 1983. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis 3:155-193. http://dx.doi.org/10.1016/S0272-6386(83)80060-2.
20. Peloquin CA, Namdar R, Singleton MD, Nix DE. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18. http://dx.doi.org/10.1378/chest.115.1.12.
21. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15(Suppl A):125-130.
22. th ed. Williams & Wilkins Co., Baltimore, MD.
23. Werth BJ, Steed ME, Kaatz GW, Rybak MJ. 2013. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect." Antimicrob Agents Chemother 57:2664-2668. http://dx.doi.org/10.1128/AAC.02308-12.
24. Falagas ME, Kapaskelis AM, Kouranos VD, Kakisi OK, Athanassa Z, Karageorgopoulos DE. 2009. Outcome of antimicrobial therapy in documented biofilm-associated infections: a review of the available clinical evidence. Drugs 69:1351-1361. http://dx.doi.org/10.2165/00003495-200969100-00005.
25. Stewart PS, Costerton JW. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138. http://dx.doi.org/10.1016/S0140-6736(01)05321-1.
26. Frank KL, Reichert EJ, Piper KE, Patel R. 2007. In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob Agents Chemother 51:888-895. http://dx.doi.org/10.1128/AAC.01052-06.
27. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. 2005. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 49:3501-3512. http://dx.doi.org/10.1128/AAC.49.8.3501-3512.2005.
28. Barber KE, Ireland CE, Bukavyn N, Rybak MJ. 2014. Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther 3:35-43. http://dx.doi.org/10.1007/s40121-014-0023-0.
29. Roveta S, Marchese A, Schito GC. 2008. Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp. Int J Antimicrob Agents 31:321-328. http://dx.doi.org/10.1016/j.ijantimicag.2007.11.012.
30. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillinresistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 53:158-163. http://dx.doi.org/10.1093/cid/cir340.
31. Sundareshan V, Modi J, Bergman S, Koirala J. 2012. Possible antagonism with use of ceftaroline and rifampin to treat methicillin-resistant Staphylococcus aureus infection. Int J Infect Dis 16S:e421. http://dx.doi.org/10.1016/j.ijid.2012.05.583.
32. LaPlante KL, Woodmansee S. 2009. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother 53:3880-3886. http://dx.doi.org/10.1128/AAC.00134-09.